VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 107 filers reported holding VAXCYTE INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,876,232 | -1.7% | 429,114 | -3.8% | 0.00% | 0.0% |
| Q2 2023 | $22,265,499 | +19.2% | 445,845 | -10.5% | 0.00% | 0.0% |
| Q1 2023 | $18,678,195 | -2.5% | 498,351 | +24.8% | 0.00% | 0.0% |
| Q4 2022 | $19,149,503 | +63.5% | 399,364 | -18.1% | 0.00% | +33.3% |
| Q3 2022 | $11,709,000 | +52.3% | 487,883 | +38.1% | 0.00% | +50.0% |
| Q2 2022 | $7,690,000 | -7.0% | 353,381 | +3.2% | 0.00% | 0.0% |
| Q1 2022 | $8,273,000 | +75.2% | 342,551 | +72.6% | 0.00% | +100.0% |
| Q4 2021 | $4,722,000 | -24.4% | 198,477 | -19.4% | 0.00% | 0.0% |
| Q3 2021 | $6,248,000 | +49.6% | 246,294 | +32.7% | 0.00% | 0.0% |
| Q2 2021 | $4,177,000 | +16.8% | 185,585 | +2.5% | 0.00% | 0.0% |
| Q1 2021 | $3,577,000 | -54.5% | 181,100 | -38.8% | 0.00% | -50.0% |
| Q4 2020 | $7,863,000 | +184.6% | 295,908 | +238.5% | 0.00% | +100.0% |
| Q2 2020 | $2,763,000 | – | 87,424 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |